Cancer Management and Research最新文献

{"title":"Multicenter Development of a Clinical-Molecular Nomogram for Predicting Survival in Lung Cancer Brain Metastasis Patients.","authors":"Xiansheng Qiu, Zhenwei Lu, Chongfei Li, Sifang Chen, Xiaoping Zhou, Zhizhu Peng, Li Chen, Wen Peng Zhao, JingJing Shi, Jiawei He, Xuewei Xia, Zhanxiang Wang","doi":"10.2147/CMAR.S538752","DOIUrl":"10.2147/CMAR.S538752","url":null,"abstract":"<p><strong>Background: </strong>Lung cancer brain metastasis (LCBM) accounts for 40-50% of intracranial malignancies, with emerging evidence of alternative metastatic pathways circumventing the blood-brain barrier. Existing prognostic models lack validation in Asian populations and molecular stratification. This multicenter study aimed to develop a clinical nomogram integrating clinicopathological and molecular determinants for personalized LCBM management.</p><p><strong>Methods: </strong>Retrospective analysis of 522 surgically treated LCBM patients (2015-2021) from four Chinese institutions was conducted. Patients were randomized 7:3 into training (n=365) and validation (n=157) cohorts. Multivariate Cox regression identified independent prognostic factors, which were incorporated into a nomogram predicting 6-/12-/18-month overall survival (OS). Model performance was assessed via time-dependent ROC curves (AUC), calibration plots, and decision curve analysis (DCA).</p><p><strong>Results: </strong>The median OS after neurosurgery was 9 months (range: 4-18 months), with 6-, 12-, and 18-month survival rates of 86.2%, 46.7%, and 17.2%, respectively. Independent predictive factors included brain metastasis size ≥5 cm, Leptomeningeal metastasis(LM), EGFR mutation with TKI treatment, and extracranial metastases. The nomogram demonstrated robust discriminative ability and calibration. EGFR-mutant patients receiving postoperative TKIs showed significantly prolonged survival attributable to enhanced blood-brain barrier permeability. Finally, the authors developed a web-based dynamic nomogram for LCBM patients to facilitate clinical implementation.</p><p><strong>Conclusion: </strong>This study establishes a validated prognostic model integrating tumor burden, EGFR mutation status, and metastatic patterns. It demonstrates that EGFR-guided TKI therapy and bone metastasis surveillance critically influence LCBM outcomes. The nomogram provides a quantifiable framework for risk-adapted therapeutic decisions, advancing precision oncology in neuro-oncology practice.</p>","PeriodicalId":9479,"journal":{"name":"Cancer Management and Research","volume":"17 ","pages":"1881-1895"},"PeriodicalIF":2.6,"publicationDate":"2025-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12415090/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145028924","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Multimodal Psychobehavioral Interventions for Lung Cancer-Related Pain: A Protocol Development and Validation Study Examining the Mediating Role of Self-Efficacy in the Relationship Between Pain Perception and Adaptive Coping Strategies.","authors":"Bing Liu, Yongyong Ding, Junfei Xu, Xuehai Wu, Xiaofeng Yang, Yi Liu, Hong Deng","doi":"10.2147/CMAR.S537477","DOIUrl":"10.2147/CMAR.S537477","url":null,"abstract":"<p><strong>Objective: </strong>To evaluate the effects of a comprehensive intervention program on cancer pain and self-efficacy in patients with lung cancer.</p><p><strong>Methods: </strong>A total of 120 lung cancer patients with cancer pain who received treatment from January 2021 to December 2023 at The First People's Hospital of Zunyi were enrolled in this study. A within-subject design was used, comparing patients' pain and self-efficacy scores before and after a comprehensive intervention. The intervention included pharmacologic therapy, psychological counseling, health education, mindfulness training, social support, and personalized rehabilitation. Pain was assessed using the Numerical Rating Scale (NRS), and self-efficacy was measured with the Chronic Disease Self-Efficacy Scale (CDSE). Subgroup and regression analyses were performed to explore related factors.</p><p><strong>Results: </strong>After intervention, the average NRS pain score decreased significantly from 7.2 ± 1.5 to 3.8 ± 1.2 (↓47.22%, t=15.6, p<0.001). Patients participating in mindfulness training reported a greater reduction in pain than non-participants (p=0.013). The total CDSE score increased from 52.3 ± 8.7 to 72.4 ± 9.5 (t=12.4, p<0.001), with significant improvements across all subscales (self-management, general efficacy, goal achievement, and problem-solving; all p<0.001). Subgroup analyses revealed that the improvements were consistent across gender, age groups, and education levels (p>0.05). Logistic regression identified pain relief (NRS score) as a significant predictor of enhanced self-efficacy (OR=1.403, 95% CI: 1.125-1.885, p=0.002), whereas age and education were not significant.</p><p><strong>Conclusion: </strong>A comprehensive, multimodal intervention significantly improved both pain control and self-efficacy in patients with lung cancer-related pain. The effects were robust across demographic subgroups, with pain relief being a key factor influencing self-efficacy. These findings support the integration of psychological and behavioral strategies in pain management for cancer patients.</p>","PeriodicalId":9479,"journal":{"name":"Cancer Management and Research","volume":"17 ","pages":"1871-1880"},"PeriodicalIF":2.6,"publicationDate":"2025-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12415088/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145028958","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advances in PSMA-Targeted Radionuclide Therapy for Metastatic Castration-Resistant Prostate Cancer.","authors":"Jie Wang, Hui Yuan, Jianan Xu, Chongyi Yang","doi":"10.2147/CMAR.S538367","DOIUrl":"10.2147/CMAR.S538367","url":null,"abstract":"<p><p>Prostate cancer (PCa) is the most common tumor for men in the genital system. Despite several new therapies approved in the past decades, 34,700 patients die on a regular basis in 2023 in America. Recently radioisotopic therapies have shown the delightful results in the PCa treatment, which made FDA approved lutetium-177 for adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castrate-resistant prostate cancer (mCRPC). Many other clinical trials are also in progress in various settings. Both monotherapy and combination studies are underway. However, because of several limitations existed in these clinical trials and alarmed long-term nephrotoxicity of PSMA-targeted therapy, we should be more prudent to this therapy. In this review, we evaluates the evolving clinical and preclinical landscape of PSMA-targeted therapy, as well as the potential biomarkers for evaluating the therapeutic response.</p>","PeriodicalId":9479,"journal":{"name":"Cancer Management and Research","volume":"17 ","pages":"1859-1869"},"PeriodicalIF":2.6,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12412599/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145013837","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Neoadjuvant Docetaxel-Carboplatin-Trastuzumab Therapy in HER2-Positive Breast Cancer: A Single-Center Experience from Vietnam.","authors":"Hung Nguyen Quang, Phuong Dao Manh, Mai Nguyen Thi Hoa, Doan Tran Thi","doi":"10.2147/CMAR.S537882","DOIUrl":"10.2147/CMAR.S537882","url":null,"abstract":"<p><strong>Purpose: </strong>To evaluate the efficacy of neoadjuvant therapy and identify associated factors influencing treatment response in patients with HER2-positive breast cancer.</p><p><strong>Subjects and methods: </strong>A prospective, longitudinal study of 40 women with a mean age of 50.68 ± 10.53 years diagnosed with HER2-positive breast cancer. All patients received neoadjuvant treatment using Docetaxel-Carboplatin-Trastuzumab (TCH) regimens. These patients were evaluated for treatment response based on the Response Evaluation Criteria In Solid Tumors (RECIST) after six 21-day treatment cycles.</p><p><strong>Results: </strong>The proportion of good responders was 45.0% (18/40 patients). Younger age, earlier clinical stage, and lower baseline serum CA15-3 levels were significantly associated with a better response (p < 0.05). The incidence of adverse events was also significantly lower in good responders (p < 0.05). Multivariate analysis identified younger age and lower CA15-3 concentration as independent predictors of favorable response, with area under the Receiver Operating Characteristic (ROC) curves (AUC) of 0.758 and 0.821, respectively (p = 0.006 and p = 0.001).</p><p><strong>Conclusion: </strong>Neoadjuvant treatment using the Docetaxel-Carboplatin-Trastuzumab regimen provides favorable clinical outcomes in HER2-positive breast cancer patients. Baseline CA15-3 levels may serve as a useful predictor of treatment response.</p>","PeriodicalId":9479,"journal":{"name":"Cancer Management and Research","volume":"17 ","pages":"1851-1858"},"PeriodicalIF":2.6,"publicationDate":"2025-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12410382/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145013791","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pain and Its Treatment Among Outpatients with Malignant Tumors in China.","authors":"Peiyang Mao, Xin Tian, Yinxia Zhan, Feng Gao, Xiangyu Tan, Hongfan Yu, Xiaobo Du, Jie Li, Gang Feng, Jingyu Zhang, Qiuling Shi","doi":"10.2147/CMAR.S532474","DOIUrl":"10.2147/CMAR.S532474","url":null,"abstract":"<p><strong>Background: </strong>Pain is common among patients with malignant tumors. It significantly impacts quality of life, yet over 80% of advanced cancer patients lack adequate pain management. Despite improvements in China's pain management program, challenges remain, especially for older adults and outpatient care.</p><p><strong>Methods: </strong>We evaluated pain intensity management adequacy using a 0-10 numerical rating scale (NRS), and Pain Management Index (PMI) at an outpatient oncology clinic. Differences and changes in pain levels were statistically analyzed using <i>t</i>-test, rank-sum, and chi-square tests. Factors associated with inadequate pain management were identified using multivariate logistic regression.</p><p><strong>Results: </strong>Among 589 participants, 45.41% scored moderate to severe pain ≥ 4, and 81.32% experienced inadequate pain management (PMI < 0). Pain was more severe among older, than younger patients (4.15 ± 2.89 vs 3.65 ± 2.41, <i>P</i> < 0.001) and pain management was inadequate in older compared with younger patients (75.47% vs 89.87%). Undergoing targeted or immune adjuvant therapy (odds ratio [OR], 3.206; 95% confidence interval [CI], 1.538-6.684) and poor physical status (OR, 5.053; 95% CI, 2.023-12.622) emerged as significant risk factors for inadequate pain management.</p><p><strong>Conclusion: </strong>Pain management is challenging for patients aged ≥60 years. Therefore, tailored interventions are needed to enhance care quality.</p>","PeriodicalId":9479,"journal":{"name":"Cancer Management and Research","volume":"17 ","pages":"1843-1850"},"PeriodicalIF":2.6,"publicationDate":"2025-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12407010/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144999698","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bacteriological Identification, Characterization and Changes of Feces Microbiome in Prostate Cancer Patients Undergoing Radiotherapy.","authors":"Aleksandra Bogumiła Florkiewicz, Paweł Fijałkowski, Piotr Fijałkowski, Michał Złoch, Agnieszka Ludwiczak, Dorota Gabryś, Wioletta Miśta, Jolanta Mrochem-Kwarciak, Anna Jędrzejewska, Ewa Telka, Małgorzata Rabsztyn, Grażyna Czeszewska-Rosiak, Radik Mametov, Andrzej Tretyn, Paweł Pomastowski","doi":"10.2147/CMAR.S517416","DOIUrl":"10.2147/CMAR.S517416","url":null,"abstract":"<p><strong>Purpose: </strong>To investigate the bacteriological characteristics of the gut microbiome in patients with prostate cancer and changes during and after radiation therapy.</p><p><strong>Patients and methods: </strong>Forty-one prostate cancer (PCa) patients treated with radiation therapy were included in the study. Fecal samples were collected at three points: before gold marker implantation into the prostate gland (K1), at the start (K2), and last day of radiotherapy (K3). Microbial identification was performed using MALDI-TOF MS, which allowed for precise identification at the species and genus levels. Blood biochemical parameters were assessed, and correlation analyses were performed.</p><p><strong>Results: </strong>In total, 291 microbial isolates were identified, with the most common genera being <i>Escherichia</i> (N=120), <i>Streptococcus</i> (N=31), and <i>Enterococcus</i> (N=30). A significant decrease in <i>E. coli</i> was observed in K3 compared with K1 and K2, whereas <i>Citrobacter</i> appeared exclusively at K2. Additionally, liver enzyme levels decreased, and IL-6 levels increased during treatment. These findings indicate significant shifts in the gut microbiota due to radiotherapy.</p><p><strong>Conclusion: </strong>Radiation therapy alters the gut microbiota composition in patients with PCa, reduces microbial diversity, and promotes the growth of opportunistic pathogens. These changes are linked to biochemical parameters, suggesting a potential impact on health. Further research is needed to explore microbiome-targeted interventions during treatment.</p>","PeriodicalId":9479,"journal":{"name":"Cancer Management and Research","volume":"17 ","pages":"1825-1841"},"PeriodicalIF":2.6,"publicationDate":"2025-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12405716/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144999728","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Myasthenia Gravis-Like Symptoms Following Immune Checkpoint Inhibitor Therapy for Hepatocellular Carcinoma: A Case Report.","authors":"Fushuang Ha, Haoyu Wang, Junjun Cai, Jing Liang, Hua Liu","doi":"10.2147/CMAR.S524543","DOIUrl":"10.2147/CMAR.S524543","url":null,"abstract":"<p><p>We describe the case of an older male patient with hepatocellular carcinoma and a history of hepatitis B virus-related cirrhosis and type 2 diabetes mellitus. At 12 weeks after treatment with transcatheter arterial chemoembolization (TACE) combined with systemic therapy using lenvatinib and camrelizumab, the patient was found to have progressive disease, based on the modified Response Evaluation Criteria in Solid Tumors (mRECIST) criteria. He also exhibited symptoms such as left eyelid ptosis and limitations in inward, upward, and downward movements of the left eye. The possibility of immune checkpoint inhibitor-induced myasthenia gravis was considered. After relevant examinations including electromyography and repetitive nerve stimulation, a diagnosis of oculomotor nerve palsy induced by diabetes-related microvascular dysfunction was ultimately considered. Subsequently, the patient was treated with camrelizumab combined with regorafenib and TACE therapy and was concurrently subjected to stricter glycemic control and neurotrophic treatment. Three months later, the ocular symptoms disappeared, and the mRECIST assessment revealed the achievement of a partial response. At the time of manuscript submission, the overall survival of the patient had reached 81 months.</p>","PeriodicalId":9479,"journal":{"name":"Cancer Management and Research","volume":"17 ","pages":"1819-1823"},"PeriodicalIF":2.6,"publicationDate":"2025-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12399299/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144943473","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Moxibustion Enhances Chemotherapy of Breast Cancer by Affecting Tumor Microenvironment [Retraction].","authors":"","doi":"10.2147/CMAR.S563254","DOIUrl":"10.2147/CMAR.S563254","url":null,"abstract":"<p><p>[This retracts the article DOI: 10.2147/CMAR.S249797.].</p>","PeriodicalId":9479,"journal":{"name":"Cancer Management and Research","volume":"17 ","pages":"1801-1802"},"PeriodicalIF":2.6,"publicationDate":"2025-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12400188/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144991701","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Successful Treatment of Diffuse Large B-Cell Lymphoma and Antisynthetase Syndrome with Bispecific Antibody Glofitamab.","authors":"Chong Wei, Mei Zhang, Danqing Zhao, Wei Zhang, Yan Zhang","doi":"10.2147/CMAR.S536049","DOIUrl":"10.2147/CMAR.S536049","url":null,"abstract":"<p><p>Glofitamab, a CD20×CD3 T-cell-engaging bispecific monoclonal antibody, has emerged as a promising therapeutic agent for relapsed/refractory B-cell non-Hodgkin lymphoma. The advent of chimeric antigen receptor T-cell therapy and T-cell-engaging bispecific antibodies has also stimulated growing interest in their potential application in autoimmune diseases. Here, we report a case of diffuse large B-cell lymphoma (DLBCL) in a patient with a long-standing history of antisynthetase syndrome (ASyS). The patient achieved complete remission of lymphoma with third-line glofitamab therapy after failure of first-line R-CHOP and second-line polatuzumab vedotin combined with lenalidomide. Remarkably, her ASyS symptoms, which had been refractory to multiple immunosuppressive agents (cyclosporine, methotrexate, hydroxychloroquine) and targeted therapies (tofacitinib, baricitinib), also resolved following glofitamab treatment. This case underscores the potential of glofitamab not only as an effective treatment for refractory DLBCL but also as a novel therapeutic strategy for concomitant autoimmune manifestations, warranting further investigation in the context of autoimmune disorders.</p>","PeriodicalId":9479,"journal":{"name":"Cancer Management and Research","volume":"17 ","pages":"1813-1817"},"PeriodicalIF":2.6,"publicationDate":"2025-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12399897/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144991726","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Analysis of the Diagnostic Efficacy and Clinical Utility of Multiparametric MRI in Prostate Cancer Diagnosis.","authors":"Xiongbo Lou","doi":"10.2147/CMAR.S543435","DOIUrl":"10.2147/CMAR.S543435","url":null,"abstract":"<p><strong>Objective: </strong>To evaluate the diagnostic efficacy and clinical relevance of multiparametric MRI (mpMRI) in detecting prostate cancer (PCA).</p><p><strong>Methods: </strong>This retrospective study analyzed 64 patients with suspected PCA who underwent MRI and were pathologically diagnosed with either PCA (n=33) or benign prostatic lesions (BPL, n=31). Imaging characteristics were assessed using T2-weighted imaging (T2WI), diffusion-weighted imaging (DWI), and dynamic contrast-enhanced MRI (DCE-MRI). DWI signal intensities at b=50 and b=800s/mm² and apparent diffusion coefficient (ADC) values were compared. Perfusion parameters, including Ktrans, Ve, and Kep, were also analyzed. Spearman correlation assessed associations between imaging parameters and PCA occurrence. Receiver operating characteristic (ROC) curves evaluated the diagnostic performance of each sequence and their combination.</p><p><strong>Results: </strong>PCA lesions showed hypointensity on T2WI, hyperintensity on DWI, and type II/III curves on DCE-MRI. Signal intensities at b=50 and b=800s/mm² and ADC values were significantly lower in PCA than in BPL (P < 0.05), whereas Ktrans, Ve, and Kep were significantly higher (P < 0.05). Spearman analysis showed negative correlations between PCA occurrence and b=50, b=800 signal intensities and ADC (r = -0.547, -0.529, -0.601), and positive correlations with Ktrans, Ve, and Kep (r = 0.516, 0.538, 0.552; all P < 0.05). ROC analysis revealed AUCs of 0.834 (T2WI), 0.819 (DWI), 0.696 (DCE-MRI), and 0.902 (combined T2WI+DWI), with the combined approach yielding the highest diagnostic accuracy.</p><p><strong>Conclusion: </strong>mpMRI parameters including DWI signal intensity, ADC, and DCE-MRI perfusion values are significantly associated with PCA. Combined application of T2WI and DWI improves diagnostic accuracy and may offer greater clinical value than individual sequences.</p>","PeriodicalId":9479,"journal":{"name":"Cancer Management and Research","volume":"17 ","pages":"1803-1812"},"PeriodicalIF":2.6,"publicationDate":"2025-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12399885/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144991740","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}